ENVERIC BIOSCIENCES, INC. Acquisitions, Net of Cash Acquired
ENVERIC BIOSCIENCES, INC. (ENVB) reported Acquisitions, Net of Cash Acquired of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2020-11-16
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2019-06-30 was $100.00K, a 9999900.00% increase year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for fiscal 2019 was $200.00K, a 94.51% decline from fiscal 2018.
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for fiscal 2018 was $3.65M, a 2109.23% increase from fiscal 2017.
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for fiscal 2017 was $165.02K, a 97.49% decline from fiscal 2016.
- ENVERIC BIOSCIENCES, INC. payments to acquire businesses, net of cash acquired for fiscal 2016 was $6.56M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 3 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 12 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-08-12 | $0.00 derived: sum of 3 quarters · filed 2020-11-16 | $100.00K derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $100.00K derived: sum of 3 quarters · filed 2020-11-16 | $200.00K 10-K/A · filed 2020-08-12 | ||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $100.00K derived: sum of 2 quarters · filed 2020-11-16 | $200.00K 10-Q · filed 2020-11-16 | $200.00K derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $200.00K 10-Q · filed 2020-08-14 | $200.00K derived: sum of 3 quarters · filed 2020-08-14 | $2.78M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $100.00K 10-Q · filed 2020-05-15 | $100.00K derived: sum of 2 quarters · filed 2020-08-12 | $2.68M derived: sum of 3 quarters · filed 2020-08-12 | $2.68M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2018-12-31 | $1.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-12 | $2.58M derived: sum of 2 quarters · filed 2020-08-12 | $2.58M derived: sum of 3 quarters · filed 2020-08-12 | $3.65M 10-K/A · filed 2020-08-12 | ||||
| 2018-09-30 | $2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.58M derived: sum of 2 quarters · filed 2019-11-08 | $3.65M 10-Q · filed 2019-11-08 | $3.75M derived: sum of 4 quarters · filed 2019-11-08 | ||||
| 2018-06-30 | $1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $1.07M 10-Q · filed 2019-08-14 | $1.18M derived: sum of 3 quarters · filed 2019-08-14 | $1.18M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | $1.07M 10-Q · filed 2019-05-14 | $1.18M derived: sum of 2 quarters · filed 2019-05-14 | $1.18M derived: sum of 3 quarters · filed 2019-05-14 | $1.18M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $109.33K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $109.33K derived: sum of 2 quarters · filed 2019-03-26 | $109.33K derived: sum of 3 quarters · filed 2019-03-26 | $165.02K 10-K · filed 2019-03-26 | $804.04K 10-K · filed 2018-04-02 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $55.69K 10-Q · filed 2018-11-14 | $694.71K 10-Q · filed 2017-11-13 | -$2.16M derived: sum of 4 quarters · filed 2018-11-14 | |||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $55.69K 10-Q · filed 2018-08-14 | $694.71K 10-Q · filed 2017-08-14 | -$2.16M derived: sum of 3 quarters · filed 2018-08-14 | $3.39M derived: sum of 4 quarters · filed 2018-08-14 | |||
| 2017-03-31 | $55.69K 10-Q · filed 2018-05-15 | $311.47K 10-Q · filed 2017-05-12 | -$2.16M derived: sum of 2 quarters · filed 2018-05-15 | $3.39M derived: sum of 3 quarters · filed 2018-05-15 | $4.90M derived: sum of 4 quarters · filed 2018-05-15 | |||
| 2016-12-31 | -$2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $3.33M derived: sum of 2 quarters · filed 2018-04-02 | $4.84M derived: sum of 3 quarters · filed 2018-04-02 | $6.56M 10-K · filed 2018-04-02 | ||||
| 2016-09-30 | $5.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $7.06M derived: sum of 2 quarters · filed 2017-11-13 | $8.78M 10-Q · filed 2017-11-13 | |||||
| 2016-06-30 | $1.51M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-14 | $3.23M 10-Q · filed 2017-08-14 | ||||||
| 2016-03-31 | $1.72M 10-Q/A · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |